• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Meiwu Technology Company Limited

    3/19/26 9:05:06 AM ET
    $WNW
    Catalog/Specialty Distribution
    Consumer Discretionary
    Get the next $WNW alert in real time by email
    6-K 1 form6-k.htm 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of March 2026

     

    Commission File Number: 001-39803

     

    Meiwu Technology Company Limited

    (Translation of registrant’s name into English)

     

    Unit 304-3, No.19, Wanghai Road, Siming District

    Xiamane, Fujian, People’s Republic of China

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

     

    Closing of $14 Million Registered Direct Offering

     

    On March 18, 2026, Meiwu Technology Company Limited’s (the “Company”) entered into a certain securities purchase agreement with certain investors for the purchase and sale of an aggregate of 6,999,996 of the Company’s ordinary shares, no par value each (the “Ordinary Shares”) and warrants (the “Warrants”) to purchase up to 6,999,996 ordinary shares at an exercise price of $2.00 per share. The gross proceeds from this offering to the Company were approximately $14 million, before deducting placement agent fees and other estimated expenses payable by the Company.

     

    The Warrants will be immediately exercisable and will expire in one year following the initial issuance date. A holder of Warrants may, at any time and in its sole discretion, exercise its Warrants in whole or in part by means of a “zero price exercise” option in which the holder is entitled to receive a number of Ordinary Shares equal to the product of (a) the number of Ordinary Shares that would be issuable upon exercise of the Warrant in accordance with the terms of such Warrant if such exercise were by means of a cash exercise rather than a cashless exercise and (b) the quotient obtained by dividing (i) the exercise price minus the lowest VWAP (as defined in the form of Warrant) of the Ordinary Shares during the ten (10) trading days immediately prior to the applicable exercise date (such VWAP, the “Low Price”) by (ii) 50% of the Low Price. This “zero price exercise” option is only available at a time when the applicable Low Price is lower than the then applicable exercise price. At no time can the Low Price be lower than $0.40 (the “Floor Price”). Accordingly, if the holder elects the zero price exercise option, the number of shares of Ordinary Shares issuable upon exercise of the Warrants could increase to up to an aggregate of 83,999,952, assuming the Low Price equals the Floor Price at the time of such election. 

     

    The securities in the Offering are being offered pursuant to a securities purchase agreement with certain investors (the “Securities Purchase Agreement”) and the Company’s registration statement on Form F-3 (File No. 333-292111), as amended, which was initially filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 12, 2025 and was declared effective by the SEC on February 24, 2025.

     

    Pursuant to the Securities Purchase Agreement, the Company has agreed not to (i) issue or enter into an agreement to issue any Ordinary Shares or Ordinary Share Equivalents (as defined in the Securities Purchase Agreement), or (ii) file any registration statement or amendment or supplement thereto, subject to certain exceptions, for a period of 45 days beginning on the date of the Securities Purchase Agreement and ending on 45 days following the closing date. The Company has also agreed not to enter into or effect any Variable Rate Transaction (as defined in the Securities Purchase Agreement) beginning on the date of the Securities Purchase Agreement and ending on 45 days following the closing date.

     

    In connection with the offering, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Univest Securities, LLC (the “Placement Agent”), pursuant to which the Placement Agent acted as sole placement agent for this offering and would receive at the closing of the offering a cash fee equal to 7% of the gross proceeds, a non-accountable expenses allowance of 0.5% of the gross proceeds of the offering and reimbursement for legal fees and other out-of-pocket fees, costs and expenses in the amount of up to $100,000.

     

    In addition, on March 17, 2026, each of the directors and officers of the Company, as well as shareholders who beneficially own more than 5% of the issued and outstanding Ordinary Shares, entered into a certain lock-up agreements (the “Lock-Up Agreements”), pursuant to which each of them has agreed, among other things, not to sell or dispose of any Ordinary Shares which are or will be beneficially owned by them for ninety (90) days following the closing of the offering.

     

    The offering closed on March 18, 2026. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. However, the management of the Company will have discretion in allocating the net proceeds in accordance with the above priorities and purposes, depending on general operating costs and expenditures and the changing needs of the Company’s business.

     

     

     

     

    Copies of the (i) form of Warrant, (ii) form of Securities Purchase Agreement, (iii) Placement Agency Agreement, and (vi) form lock-up agreement are attached hereto as Exhibits 4.1, 10.1, 10.2, and 10.3, respectively, and are incorporated by reference herein. The foregoing summaries of the terms of each agreement mentioned above are subject to, and qualified in their entirety by, such documents.

     

    This report does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. 

     

    Forward-Looking Statements

     

    Certain statements in this current report on Form 6-K are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.

     

    EXHIBIT INDEX

     

    Number   Description of Exhibit
         
    4.1   The Form of Warrants

    5.1

      Legal Opinion of Conyers Dill & Pearman
    10.1   The Form of Securities Purchase Agreement
    10.2   The Placement Agency Agreement, dated March 17, 2026

    10.3

     

    The Form of Lock-Up Agreement

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Meiwu Technology Company Limited
         
      By: /s/ Zhichao Yang
        Zhichao Yang
        Chief Executive Officer
         
    Date: March 19, 2026    

     

     

     

     

    Get the next $WNW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WNW

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $WNW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Univest Securities, LLC Announces Closing of $14.0 Million Registered Direct Offering for its Client Meiwu Technology Co Ltd (NASDAQ: WNW)

    New York, March 18, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the "Offering") of $14.0 million for its client Meiwu Technology Co Ltd (NASDAQ:WNW)(the "Company" or "Meiwu"), a company engaged in the research, development, and sale of functional skincare products and related services in the skincare industry. Under the terms of the securities purchase agreement, the Company has agreed to sell to certain investors an aggregate of 6,999,996 of the Company's ordinary shares, no par value each (the "

    3/18/26 5:00:00 PM ET
    $WNW
    Catalog/Specialty Distribution
    Consumer Discretionary

    Meiwu Technology Co Ltd Announces $14 Million Registered Direct Offering

    SHENZHEN, China, March 17, 2026 /PRNewswire/ -- Meiwu Technology Co Ltd (NASDAQ:WNW) (the "Company"), today announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of 6,999,996 of the Company's ordinary shares, no par value each (the "Shares") at a purchase price of $2.00 per share in a registered direct offering. The Company also agreed to issue to the same investors warrants (the "Warrants") to purchase up to 6,999,996 ordinary shares at an exercise price of $2.00 per share. The Warrants will have a 1-year term from the date of issuance.The aggregate gross proceeds to the Company of this offering are expected to be approxim

    3/17/26 9:25:00 AM ET
    $WNW
    Catalog/Specialty Distribution
    Consumer Discretionary

    WNW Announces Strategic AI Insights Initiative to Support Functional Skincare Product Innovation

    SHENZHEN, China, March 16, 2026 /CNW/ -- Meiwu Technology Company Limited ("WNW" or the "Company"), (NASDAQ:WNW) announced today that the Company is introducing a strategic artificial intelligence ("AI") insights initiative as part of its ongoing efforts to enhance research collaboration and operational efficiency across its functional skincare business. Through this initiative, the Company plans to explore the application of AI-assisted data analysis tools to support internal research coordination, product formulation analysis, and collaboration with external research partners. The initiative is expected to assist the Company in organizing and evaluating a growing body of research data, inc

    3/16/26 9:20:00 AM ET
    $WNW
    Catalog/Specialty Distribution
    Consumer Discretionary

    $WNW
    SEC Filings

    View All

    SEC Form 6-K filed by Meiwu Technology Company Limited

    6-K - Meiwu Technology Co Ltd (0001787803) (Filer)

    3/19/26 9:05:06 AM ET
    $WNW
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 424B5 filed by Meiwu Technology Company Limited

    424B5 - Meiwu Technology Co Ltd (0001787803) (Filer)

    3/18/26 11:18:25 AM ET
    $WNW
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 6-K filed by Meiwu Technology Company Limited

    6-K - Meiwu Technology Co Ltd (0001787803) (Filer)

    3/17/26 12:52:40 PM ET
    $WNW
    Catalog/Specialty Distribution
    Consumer Discretionary

    $WNW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Meiwu Technology Company Limited

    SC 13G - Meiwu Technology Co Ltd (0001787803) (Subject)

    10/31/23 4:24:23 PM ET
    $WNW
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form SC 13G filed by Meiwu Technology Company Limited

    SC 13G - Meiwu Technology Co Ltd (0001787803) (Subject)

    10/31/23 4:22:35 PM ET
    $WNW
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form SC 13G filed by Meiwu Technology Company Limited

    SC 13G - Meiwu Technology Co Ltd (0001787803) (Subject)

    10/31/23 4:19:58 PM ET
    $WNW
    Catalog/Specialty Distribution
    Consumer Discretionary

    $WNW
    Financials

    Live finance-specific insights

    View All

    Meiwu Technology Company Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

    Shenzhen, China, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Meiwu Technology Company Limited ("WNW" or the "Company"), (NASDAQ:WNW) announced today that on September 10, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that the minimum bid price per share for its ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company's ordinary shares on Nasdaq. Under the Nasdaq Li

    9/11/24 4:15:00 PM ET
    $WNW
    Catalog/Specialty Distribution
    Consumer Discretionary

    Meiwu Technology Co., Limited Received Nasdaq Notification Letter Related to Late Filing of Annual Report on Form 20-F

    Shenzhen, China, June 05, 2024 (GLOBE NEWSWIRE) -- Meiwu Technology Co., Limited (NASDAQ:WNW) ("Meiwu" or the "Company"), an online and mobile commerce company providing organic and green food products to customers on its online platform and in its stores, enterprise short message service ("SMS") and information technology to serve designated medical insurance institutions in China, announced today that it has received a letter from the Nasdaq Stock Market, dated May 31, 2024 (the "Deficiency Letter"), notifying the Company that it is not in compliance with the requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) because it did not timely file its annual report on

    6/5/24 9:00:00 AM ET
    $WNW
    Catalog/Specialty Distribution
    Consumer Discretionary

    Meiwu Technology Co., Limited Regains Compliance with Nasdaq Listing Requirements

    Shenzhen, China, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Meiwu Technology Co., Limited (NASDAQ:WNW) ("Meiwu" or the "Company"), an online and mobile commerce company providing organic and green food products to customers on its online platform and in its stores, enterprise short message service ("SMS") and information technology to serve designated medical insurance institutions in China. The Company today announced on January 9, 2024, it received notice from the NASDAQ Office of General Counsel that the bid price deficiency of Meiwu's ordinary shares has been cured, and Meiwu has regained compliance with NASDAQ Marketplace Rule 5550(a)(2). As a result, a previously scheduled hearin

    1/18/24 8:30:00 AM ET
    $WNW
    Catalog/Specialty Distribution
    Consumer Discretionary